PsO is a chronic immune-mediated inflammatory skin disease characterized by impaired keratinocyte proliferation and differentiation. Deucravacitinib is a first-in-class TYK2 inhibitor approved for the treatment of moderate-to-severe PsO. At a recent symposium chaired by Professor Chan, Hin-Lee Henry, Professor April Armstrong presented the 4-year efficacy and safety data of deucravacitinib from the long-term extension of the POETYK trial programs which underscored the efficacy of deucravacitinib in difficult-to-treat areas such as the scalp. In addition, Dr. Guan, Xin and Dr. Zhang, Zhen-Ying also shared their firsthand clinical experience in managing different PsO patient subgroups with deucravacitinib.